(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 32.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Ardelyx's revenue in 2026 is $427,679,000.On average, 14 Wall Street analysts forecast ARDX's revenue for 2026 to be $138,603,248,458, with the lowest ARDX revenue forecast at $128,645,493,868, and the highest ARDX revenue forecast at $149,929,545,852. On average, 14 Wall Street analysts forecast ARDX's revenue for 2027 to be $186,060,063,995, with the lowest ARDX revenue forecast at $168,476,512,228, and the highest ARDX revenue forecast at $199,286,017,375.
In 2028, ARDX is forecast to generate $246,725,540,854 in revenue, with the lowest revenue forecast at $214,725,354,062 and the highest revenue forecast at $281,613,501,180.